Woodstock Corp Boosts Holdings in Pfizer Inc. (NYSE:PFE)

Woodstock Corp raised its holdings in Pfizer Inc. (NYSE:PFE – Get Rating) by 2.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 134,130 shares of the biopharmaceutical company’s stock after purchasing an additional 2,575 shares during the quarter. Woodstock Corp’s holdings in Pfizer were worth $6,873,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the business. RB Capital Management LLC raised its position in shares of Pfizer by 6.7% in the first quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock worth $282,000 after acquiring an additional 341 shares during the period. Ironwood Wealth Management LLC. raised its position in shares of Pfizer by 1.1% in the first quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock worth $1,868,000 after acquiring an additional 400 shares during the period. United Bank raised its position in shares of Pfizer by 0.6% in the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock worth $2,416,000 after acquiring an additional 290 shares during the period. Ergoteles LLC raised its position in shares of Pfizer by 136.3% in the first quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock worth $1,903,000 after acquiring an additional 21,209 shares during the period. Finally, Mackenzie Financial Corp raised its position in shares of Pfizer by 6.4% in the first quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock worth $69,238,000 after acquiring an additional 79,887 shares during the period. 67.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

PFE has been the subject of several research analyst reports. UBS Group set a $45.00 price target on shares of Pfizer in a research report on Tuesday. Credit Suisse Group reduced their price target on shares of Pfizer from $54.00 to $50.00 and set an “outperform” rating for the company in a research report on Wednesday, February 1st. Atlantic Securities reduced their price target on shares of Pfizer from $50.00 to $46.00 and set a “neutral” rating for the company in a research report on Wednesday, February 1st. Barclays reduced their price target on shares of Pfizer from $49.00 to $44.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 1st. Finally, BMO Capital Markets cut their price objective on shares of Pfizer from $55.00 to $53.00 and set an “outperform” rating for the company in a report on Wednesday, February 1st. Nine equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $50.38.

Pfizer Stock Down 0.7 %

PFE stock opened at $40.10 on Friday. Pfizer Inc. has a fifty-two week low of $39.23 and a fifty-two week high of $56.32. The company has a quick ratio of 1.00, a current ratio of 1.22 and a debt-to-equity ratio of 0.34. The firm’s 50-day simple moving average is $43.26 and its 200 day simple moving average is $46.03. The stock has a market cap of $225.33 billion, a PE ratio of 7.32, a price-to-earnings-growth ratio of 1.33 and a beta of 0.64.

Pfizer (NYSE:PFE – Get Rating) last posted its quarterly earnings results on Tuesday, January 31st. The biopharmaceutical company reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $1.03 by $0.11. The firm had revenue of $24.30 billion for the quarter, compared to the consensus estimate of $24.40 billion. Pfizer had a net margin of 31.27% and a return on equity of 42.03%. The business’s revenue was up 1.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.08 earnings per share. As a group, sell-side analysts predict that Pfizer Inc. will post 3.33 EPS for the current year.

About Pfizer

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.